Nkarta Inc. (NKTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NKTX Stock Price Chart Interactive Chart >
NKTX Price/Volume Stats
| Current price | $5.04 | 52-week high | $20.35 |
| Prev. close | $5.07 | 52-week low | $4.83 |
| Day low | $5.03 | Volume | 296,000 |
| Day high | $5.20 | Avg. volume | 690,539 |
| 50-day MA | $6.83 | Dividend yield | N/A |
| 200-day MA | $11.91 | Market Cap | 246.02M |
Nkarta Inc. (NKTX) Company Bio
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Latest NKTX News From Around the Web
Below are the latest news stories about NKARTA INC that investors may wish to consider to help them evaluate NKTX as an investment opportunity.
Nkarta promotes David Shook to Chief Medical Officer... |
Nkarta Promotes David R. Shook, M.D., to Chief Medical OfficerSOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer. Dr. Shook has extensive expertise in cell therapy development and continues to lead Nkarta’s global clinical development and regulatory operations. “Dave has been a driving force behind the developm |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayThe biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today! |
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle (3 weekly doses) of NKX019 monotherapy; 3 partial responses deepened to CR with additional cyclesPatients with CR observed across multiple NHL histologies, including LBCLConsolidation dosing administered to 7 patients with CRs with aim to eradicate residual tumor cells and prolong responseDurable res |
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy ProgramCall scheduled for Monday, December 5, 2022 at 8:00 a.m. ETSOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, December 5, 2022 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX019, its CD19-directed CAR NK cell therapy candidate. Conference Call and Webcast |
NKTX Price Returns
| 1-mo | -4.18% |
| 3-mo | -61.23% |
| 6-mo | -62.69% |
| 1-year | -43.62% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -15.86% |
| 2022 | -60.98% |
| 2021 | -75.03% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...